Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 12/20 | 1.00 |
| ▸ | KDR | P35968 | 11/20 | 1.00 |
| ▸ | SRC | P12931 | 9/20 | 1.00 |
| ▸ | ABL1 | P00519 | 6/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.75 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.75 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.75 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.75 |
| ▸ | PRKDC | P78527 | 3/20 | 0.75 |
| ▸ | EGFR | P00533 | 2/20 | 0.75 |
| ▸ | HCK | P08631 | 2/20 | 0.75 |
| ▸ | MTOR | P42345 | 2/20 | 0.75 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.75 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.75 |
| ▸ | PLK4 | O00444 | 1/20 | 0.75 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.75 |
| ▸ | CASK | O14936 | 1/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296185 | 1.00 | RET (1.00) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL21082533 | 0.87 | RET (0.79) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL12108174 | 0.87 | SRC (0.79) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL1296690 | 0.86 | KDR (0.84) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL19464200 | 0.86 | RET (1.00) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL12422290 | 0.86 | SRC (0.77) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL12422316 | 0.86 | SRC (0.77) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL29454801 | 0.86 | SRC (1.00) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL12422325 | 0.86 | SRC (0.75) | RETKDRSRCABL1PIK3CD | |
| SCHEMBL298922 | 0.86 | SRC (1.00) | RETKDRSRCABL1PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12502414-B2 | Second generation Seneca Valley virus oncolytic therapy: compositions and methods thereof | SENECA THERAPEUTICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240100107-A1 | SENECA VALLEY VIRUS COMBINATION THERAPY TO TREAT A CANCER REFRACTORY TO A CHECKPOINT INHIBITOR | SENECA THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| US-11661423-B2 | Heterocyclic compounds as RET kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20230090520-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2023-03-23 | — | — | US | disclosed |
| US-20220249584-A1 | SECOND GENERATION SENECA VALLEY VIRUS ONCOLYTIC THERAPY: COMPOSITIONS AND METHODS THEREOF | SENECA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220087988-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | LOXO ONCOLOGY, INC. | 2022-03-24 | — | — | US | disclosed |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | MALT1, LITAF, IL2 | RET 2474/4885KDR 4765/4885SRC 2253/4885 |
| US-11661423-B2 | Heterocyclic compounds as RET kinase inhibitors | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885SRC 24/4885 |
| US-11247972-B2 | Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases | PNCK, TXK, CILK1 | RET 1197/4885KDR 4727/4885SRC 132/4885 |
| US-20220087988-A1 | FORMULATIONS OF 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZABICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE | RET, ALK, BRAF | RET 1/4885KDR 517/4885SRC 62/4885 |
| US-20240116938-A1 | Heterocyclic Compounds as RET Kinase Inhibitors | RET, HIPK4, HIPK3 | RET 1/4885KDR 793/4885SRC 24/4885 |
| US-20230090520-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | RET 1/4885KDR 787/4885SRC 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.